Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 98 | NANETS2023 | Next issue

NANETS 2023

Abstracts

Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Previous section
Clinical – Chemo/SSA/Biologics
Table of contents
Next section
Clinical – Surgery/Applied Pathology

ea0098c18 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

[68Ga] DOTA-TATE (NETSpot) PET/CT Imaging of Pulmonary Neuroendocrine Tumors

ea0098c19 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

The Impact of Post-Treatment Imaging in Peptide Receptor Radionuclide Therapy

ea0098c20 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Yttrium 90 transarterial radioembolization of neuroendocrine liver metastasis

ea0098c21 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Ratio of total uptake volume on DOTATATE vs FDG PET as a predictive marker of treatment efficacy of Lu-177-DOTATATE in metastatic pheochromocytoma

ea0098c22 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Phase 2 trial of lu-177-DOTATATE in metastatic or inoperable pheochromocytoma/paraganglioma: interim analysis results

ea0098c23 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Phase 1/2 study of Lu-177-DOTATATE in combination with olaparib in metastatic or inoperable GI neuroendocrine tumors - first results

ea0098c24 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

68Ga-DOTATATE/18F-FDG dual PET: Utility of the NETPET score in management of G2-3 WD NENs

ea0098c25 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors

ea0098c26 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

A pilot study of pembrolizumab and embolization or 90Y radioembolization for patients with metastatic well-differentiated neuroendocrine tumors

ea0098c27 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

ETCTN 10388: A first in human Phase I Trial of Triapine and Lutetium Lu 177 DOTATATE in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

ea0098c28 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

ea0098c29 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Small bowel ischemia in patients with midgut neuroendocrine tumors after treatment with 177Lutetium-Dotatate

ea0098c30 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Novel alternate (Alt) response criteria for early outcome prediction in pancreatic (P) neuroendocrine tumors (NETs): utilizing banked imaging and radiomics

ea0098c31 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

ea0098c32 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Myelodysplasia and leukemia instances after PRRT: Experience from a tertiary institution

ea0098c33 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

DOTATATE PET/CT imaging in prostate cancer: incidental observations and potential future implications

ea0098c34 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Comparative assessment of 111in-octreotide scintigraphy, 68GA-DOTATOC PET/CT and 18F-FDG PET/CT in the staging and management of neuroendocrine tumors (NETs)

ea0098c35 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Institutional retrospective review of peptide receptor radionuclide therapy use in metastatic paragangliomas and pheochromocytomas

ea0098c37 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Initial Experience Using 0.55T MRI for Detection of Liver Metastases in NET Patients

ea0098c38 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Are there any clinical factors associated with PRRT-refractoriness in NET patients?

ea0098c39 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Repeat peptide receptor radionuclide therapy in neuroendocrine neoplasms: a NET center of excellence experience

ea0098c40 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Evaluation of long-term hepatic adverse events in patients receiving Peptide Receptor Radionuclide Therapy (PRRT) following BLAND embolization

ea0098c41 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate

ea0098c42 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging

Treatment with Lutetium in a real-world setting: How does it affect patient experience and their time-toxicity?

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more